<DOC>
	<DOCNO>NCT03026205</DOCNO>
	<brief_summary>This single center study evaluate pharmacokinetics ARMS-I formulation incorporate cetylpyridinium chloride ( CPC ) , administer single dose three spray orally , follow multiple dosing ( 3x daily oral spray ) day 3-6 repeat pharmacokinetic study final oral dose administer first dose day 7 ascertain CPC accumulation .</brief_summary>
	<brief_title>ARMS-I ( Formulation Cetylpyridinium Chloride -CPC )</brief_title>
	<detailed_description>ARMS Pharmaceuticals LLC intend apply approval ARMS-I prescription drug prevention influenza , rhinovirus RSV ( collectively , `` vURTI 's ) . The company plan confirm limited systemic bioavailability , conduct study characterize pharmacokinetics ARMS-I administer orally healthy adult . The primary objective study determine pharmacokinetics ARMS-I follow oral administration healthy subject . Specifically , investigator assess whether measurable systemic exposure , determine plasma pharyngeal fluid pharmacokinetic characteristic ARMS-I single multiple oral dosing . The secondary objective evaluate safety tolerability ARMS-I .</detailed_description>
	<mesh_term>Respiratory Tract Infections</mesh_term>
	<mesh_term>Common Cold</mesh_term>
	<mesh_term>Cetylpyridinium</mesh_term>
	<criteria>Men woman 18 45 year age , inclusive Ability understand consent process procedure Informed consent obtain sign Comprehension protocol , determine recruiter explain procedure Subjects agree available study visit . Subjects ask travel plan , whether staff could use alternate contact information provide . General good health determine Study Physician , without current medical illness clinically significant abnormal physical examination finding classify subject healthy Negative urine pregnancy test screen negative urine pregnancy test day initial pharmacokinetic sample female subject child bear potential Negative urine toxicity screen marijuana , cocaine metabolite , amphetamine , opiate , PCP , barbiturates , benzodiazepine Negative breathalyzer alcohol Body mass index ( BMI ) 18 35 ( inclusive ) [ weight ( kg ) ] / [ height ( ) 2 ] No tobacco/nicotine use least 3 month prior study enrollment No oral disease lesion Agreement refrain eat drinking except water 8 hour prior drug administration eat drink anything 4 hour dose day pharmacokinetic sampling Agreement subject reproductive potential use adequate method contraception study one week study drug administration . Female subject must agree use TWO reliable method contraception receive study drug 4 week study drug administration , include : condom , spermicidal gel , diaphragm , hormonal nonhormonal intrauterine device , surgical sterilization , oral contraceptive pill , depot progesterone injection , sexual abstinence . If male subject sexually active , subject partner must agree use least one list contraceptive method . If subject us abstinence become sexually active study , must agree use TWO form contraception female ONE male , list contraceptive method . Hypertension confirm systolic blood pressure &gt; 140 mmHg confirm diastolic blood pressure &gt; 90 mmHg , measure 10 15 minute rest Morbid obesity ( BMI &gt; 35 ) Current diagnosis pulmonary disease include asthma COPD , require use asthma medication within past year History current diagnosis diabetes Autoimmune disorder , systemic lupus erythematosus , Wegener 's disease , rheumatoid arthritis , among condition History malignancy except lowgrade skin cancer , ( i.e. , basal cell carcinoma surgically cure ) Chronic renal , hepatic , pulmonary disease condition could interfere absorption study drug ( e.g. , surgical resection significant proportion stomach bowel , gastric bypass , gastric banding , irritable bowel syndrome , inflammatory bowel disease ) Blood donation within previous 6 week History cardiac rhythm abnormality History prolong QT interval Prolongation QTcB interval ( i.e. , confirm QTcB interval &gt; 450 millisecond ) Clinically significant abnormal electrocardiogram screen judgment investigator , base formal ECG reading ; history cardiac abnormality , include conduction abnormality WolffParkinsonWhite Syndrome , dysrhythmias , coronary artery disease Laboratory value outside normal range Appendix follow test : blood cell count ( white blood cell count [ WBC ] , hemoglobin , platelet ) , serum chemistry ( sodium , potassium , calcium , chloride , CO2 , creatinine , glucose , BUN , AST , AP , ALT , total bilirubin , protein , albumin , amylase ) , urinalysis glucose , protein blood ( proviso retesting menstruate female ) . If CK normal range baseline , clinically significant , subject include . Positive serology result HIV , HBsAg , HCV infection Febrile illness temperature document &gt; 38Â°C within 7 day dose Pregnancy breastfeed Known allergic reaction study drug component , include ingredient present formulation . Treatment another investigational drug within 30 day dose Lack ability fully understand informed consent form . This determine recruiter/interviewer explain consent observe subject reading consent . Ingestion prescription medication , grapefruit juice , St John 's Wort start 14 day 5 halflives dose , whichever longer . Women may use oral contraceptive . Ingestion herbal supplement overthecounter medication start 7 day dose Use form tobacco , include cigarette smoking , pipe smoking , oral tobacco ; former smoker tobacco user , subject must use tobacco 90 day screen Any specific condition , judgment Principal Investigator , preclude participation could affect subject safety History current use narcotic , recreational drug use . Use &gt; 7 alcoholic beverage within 1 week Use intraoral product ( especially antiseptic ) except dental hygiene Use systemic antimicrobial agent within 30 day screen Prior current history seasonal allergy , chronic sinusitis rhinitis Presence oral lesion Use dentures Dental treatment currently progress ( implant , root canal , complex restorative procedure )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>